Skip to main content

Detailed Information

  • November 11, 2018
    1:00pm - 5:00pm
    Type: Short Course
    Capacity: 121


    Unlike marketing authorization for pharmaceuticals, mainly regulated at the European level by EMA, pricing and reimbursement decisions in Europe are managed by individual member states. Health care services are generally covered by a single public health insurer operating under the Ministry of Health supervision. As a monopoly buyer, this situation provides a leading position for the public health insurer to set reimbursement conditions. Therefore, based on each country’s set of regulations, processes, and values, wide variations exist in pricing and reimbursement decisions of pharmaceuticals. Using up-to-date governmental regulation sources and the ISPOR Global Health Care Systems Roadmap, this course will discuss health technology decision-making processes for reimbursement decisions fo...

ISPOR–The Professional Society for 
Health Economics and Outcomes Research

 

Copyright © 2026 ISPOR. All rights reserved.

International Society for Pharmacoeconomics and Outcomes Research, Inc